Search - tctmd.com

Displaying 1 - 20 of 83

Sort: Relevancy | Date

Presentation TCT 2024

Role of Inflammation in Coronary Heart Disease: Why Does it Matter

Presenter: Deepak Bhatt

October 29, 2024

Presentation TCT 2024

Inflammation- Current and Emerging Therapeutic Landscape

Presenter: Deepak Bhatt

October 29, 2024

News Conference News TCT 2022

Newer FlexNav Delivery System Improves Placement of Portico TAVI Valve

Todd Neale

September 19, 2022

News Conference News TCT 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Michael O'Riordan

September 19, 2022

Presentation TCT 2022

Long-Term Outcomes Following Catheter-Based Renal Denervation in Patients With Uncontrolled Hypertension: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

Presenter: Deepak Bhatt

September 18, 2022

Presentation TCT 2021

Finding the Sweet Spot: Balancing Reducing Ischemic Risk and Reducing Bleeding Risk with Antiplatelet Therapy

Presenter: Deepak Bhatt

November 05, 2021

Presentation TCT 2021

Antiplatelet Therapy for Patients with Diabetes Undergoing PCI

Presenter: Deepak Bhatt

November 05, 2021

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

News Conference News TCT 2018

RADIOSOUND-HTN Suggests Ultrasound May Be Best for Renal Denervation

Todd Neale

September 26, 2018

Even With PSP, Bioresorbable Scaffold Falls Short in ABSORB-COMPARE and ABSORB IV Trials

News Conference News TCT 2018

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

Michael O'Riordan

September 25, 2018

News Opinion Editor's Corner TCT 2018

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

Shelley Wood

September 25, 2018

News Conference News TCT 2018

Prematurely Halted Pilot Study Snaps Recent Winning Streak for Renal Denervation

Todd Neale

September 25, 2018

Presentation TCT 2018

Flash Debate #1: Based on What We Dont Know - Culprit Lesion Only PCI With a Conservative Approach Is the Preferred Strategy!

Presenter: Anthony H. Gershlick, Pieter C. Smits, Deepak L. Bhatt

September 24, 2018

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

Todd Neale

September 24, 2018

Presentation TCT 2018

ESC 2018 Late Breaking Trial #2 - MitraFR: What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Stephan Windecker

September 23, 2018

Presentation TCT 2018

ESC 2018 Late Breaking Trial #1 Global Leaders: What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Giuseppe Biondi-Zoccai

September 23, 2018

Presentation TCT 2018

ACC 2018 Late Breaking Trial #2- COMPASS : What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Kurt Huber

September 23, 2018

Presentation TCT 2018

ACC 2018 Late Breaking Trial #1 - ODYSSEY Outcomes: What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Otavio Berwanger, Peter Juni, Sanjay Kaul, Roxana Mehran, E. Magnus Ohman, Stuart J. Pocock, Giulio Stefanini

September 23, 2018

Presentation TCT 2018

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Presenter: Deepak L. Bhatt, Tullio Palmerini, Michael Maeng

September 23, 2018

Presentation TCT 2018

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Philip M. Urban

September 23, 2018

Advertisement

Role of Inflammation in Coronary Heart Disease: Why Does it Matter

Inflammation- Current and Emerging Therapeutic Landscape

Newer FlexNav Delivery System Improves Placement of Portico TAVI Valve

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Long-Term Outcomes Following Catheter-Based Renal Denervation in Patients With Uncontrolled Hypertension: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

Finding the Sweet Spot: Balancing Reducing Ischemic Risk and Reducing Bleeding Risk with Antiplatelet Therapy

Antiplatelet Therapy for Patients with Diabetes Undergoing PCI

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

RADIOSOUND-HTN Suggests Ultrasound May Be Best for Renal Denervation

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

Prematurely Halted Pilot Study Snaps Recent Winning Streak for Renal Denervation

Flash Debate #1: Based on What We Dont Know - Culprit Lesion Only PCI With a Conservative Approach Is the Preferred Strategy!

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

ESC 2018 Late Breaking Trial #2 - MitraFR: What I Liked and What I Question

ESC 2018 Late Breaking Trial #1 Global Leaders: What I Liked and What I Question

ACC 2018 Late Breaking Trial #2- COMPASS : What I Liked and What I Question

ACC 2018 Late Breaking Trial #1 - ODYSSEY Outcomes: What I Liked and What I Question

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content